MetaCap

CeriBell Inc. (CBLL)

NASDAQ: CBLLHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD

27.39+1.64 (+6.37%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CBLL stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.95
52-week range
14.87 – 28.89
Day range
25.58 – 27.45
Volume / Avg
655.91K / 452.64K
Beta
—

52-week range

$14.87$28.89

CBLL stock today

Shares of CeriBell (CBLL) finished higher on Nov 20 at $27.39, a gain of 6.37% or $1.64 per share, versus the S&P 500's 3.70% decline. Shares are 5.2% below their 52-week high of $28.89, set on Nov 3, 2026 and 84.2% above the 52-week low of $14.87, near the top of the past year's range. CBLL is up 24.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 79.5%.

CeriBell has posted a net loss over the last twelve months (EPS of -$1.95), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About CeriBell

Company profile

CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting.

Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
CEO
Dr. Xingjuan Chao Ph.D.
Headquarters
Sunnyvale, CA
Employees
327
IPO year
2024

Financial highlights

Full financials

In fiscal 2025, CeriBell generated $89.1 million in revenue, up 36.1% from fiscal 2024, its 2nd consecutive year of revenue growth. CeriBell reported a net loss of $53.4 million, compared with a loss of $40.5 million a year earlier. Gross margin was 87.9% (up from 86.7%) and operating margin -65.6%.

CeriBell annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue$89.06M$65.44M$45.23M
Growth+36.09%+44.71%—
Net income$-53.41M$-40.45M$-29.46M
EPS (diluted)$-1.46$-3.39$-5.56

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$31.57+15.26%

  • Strong buy 1
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $30.00High $33.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$-0.55 vs $-0.50
Surprise
-10.00%

CBLL news

All CBLL news

CeriBell peers

Health Care sector
CBLL peer companies
CompanyPrice% ChgMarket capCompare
CNMDCONMED Corporation46.56+0.39%$1.39Bvs CBLL
INMDInMode Ltd.12.42-2.20%$714.70Mvs CBLL
CVCapsoVision Inc.6.11-3.17%$327.56Mvs CBLL
ELMDElectromed Inc.22.98-1.20%$187.84Mvs CBLL
FOCLEDAP TMS S.A. ADR2.61-7.45%$123.25Mvs CBLL
VANIVivani Medical Inc.1.14+4.59%$102.83Mvs CBLL
STXSStereotaxis Inc.0.9422-6.71%$95.03Mvs CBLL
HSDTSolana Company Class A1.49-10.24%$93.70Mvs CBLL

Indexes, lists and sector

CeriBell stock FAQ

What is CeriBell's stock price today?

CBLL last traded at $27.39 as of Nov 20, 4:00 PM EST, up 6.37% on the day. Prices are delayed at least 15 minutes.

Who is CeriBell's CEO?

Dr. Xingjuan Chao Ph.D. is the chief executive officer of CeriBell Inc., which has about 327 employees.

What is the CBLL 52-week high?

The 52-week high for CBLL is $28.89 and the 52-week low is $14.87. The stock is currently 5.2% below its high.

Compare CBLL